Tyrosine Kinase Inhibitors: all 10,469 studies that test it

Page 7 of 105. Open to participants first (1,907), then studies with results posted, then the rest; newest registration first within each.

• A Study of Orelabrutinib in Patients With Primary Progressive Multiple SclerosisRecruitingNCT07067463Phase 3
• RC48 Plus Bevacizumab or Pyrotinib in HER2-Positive Metastatic Breast Cancer After T-DXd Failure: A Phase II StudyRecruitingNCT07065435Phase 2
• The Combination of Upadacitinib and High-dose Dexamethasone as First-line Treatment in Adult Immune ThrombocytopeniaNot yet recruitingNCT07064889Phase 2
• Phase I/II Study of PLB1004 Combined With Platinum-based Doublet Chemotherapy in Patients With EGFR Mutation-positiveNot yet recruitingNCT07063329Phase 1/2
• DZD8586 Combination Therapy in Patients With Diffuse Large B-cell Lymphoma (TAI-SHAN12)RecruitingNCT07059650Phase 1/2
• A Study of Osimertinib-based Adaptive Treatment Guided by ctDNA EGFRm+ Monitoring in NSCLCRecruitingNCT07058519Phase 2
• A Prospective, Open-label, Exploratory Basket Trial to Evaluate the Efficacy and Safety of Sintilimab Combined With Pyrotinib ± Chemotherapy in Patients With Advanced Digestive System TumorsNot yet recruitingNCT07053150Phase 2
• A Phase II Clinical Study of AK104/AK112 in Combination With TT-00420 Tablet for Advanced HCC.RecruitingNCT07052253Phase 2
• Fruquintinib vs Bevacizumab Combined With Irinotecan Liposome and Capecitabine as Second-Line Therapy for Advanced Metastatic Colorectal CancerNot yet recruitingNCT07051785Phase 2
• Substudy 03C: A Study of Combination Therapies in Participants With Renal Cell Carcinoma With Recurrent Disease During or After Anti-PD-(L)1 Therapy (MK-3475-03C/KEYMAKER-U03)RecruitingNCT07049926Phase 1/2
• Study to Evaluate the Maximal Use of Ruxolitinib Cream in Adult and Adolescent Participants With Hidradenitis SuppurativaRecruitingNCT07049575Phase 1
• Zanzalintinib for Metastatic Clear Cell Renal Cell Carcinoma With Bone MetastasesRecruitingNCT07043608Phase 2
• Zanzalintinib in Second Line and Beyond for the Treatment of Advanced Liver CancerRecruitingNCT07042919Phase 1/2
• Trial of 5-Fluorouracil (5FU)-Based Therapy in Combination With Fruquintinib in Patients With Locally Advanced Unresectable or Metastatic Colorectal CancerRecruitingNCT07042685Phase 2
• Asciminib as Maintenance Treatment After Cellular Therapies for Adults With Philadelphia Chromosome Positive Acute Lymphoblastic LeukemiaRecruitingNCT07040982Phase 1
• Asciminib With or Without Sildenafil for Brain TumorsNot yet recruitingNCT07039760Early Phase 1
• Pacritinib vs. Hydroxyurea in Advanced Proliferative Chronic Myelomonocytic LeukemiaRecruitingNCT07033598Phase 2
• Assessing An Oral JAK1 Inhibitor, Golidocitinib, in Patients Who Have Newly Diagnosed Peripheral T-Cell Lymphoma (JACKPOT23)Not yet recruitingNCT07032532Phase 2
• A Single-arm, Multicenter, Prospective Clinical Study of Adebrelimab Combined With Apatinib Neoadjuvant Therapy for Resectable Non-small Cell Lung CancerNot yet recruitingNCT07031154Phase 2
• Biomarker-Guided Ruxolitinib for the Prevention of Chronic Graft Versus Host Disease After Allogeneic Hematopoietic Cell TransplantationRecruitingNCT07025538Phase 1
• Medication Combinations of Dasatinib, Quercetin, Fisetin, Temozolomide, LMP744, and Autologous TLPO Vaccine for the Treatment of Previously Treated Glioma With Residual DiseaseRecruitingNCT07025226Early Phase 1
• MAVRiC Studies 2L Treatment With AV in Patients With CLL/SLL Who Have Relapsed After a Course of BTKi + BCL2i Combination, With or Without ObinutuzumabRecruitingNCT07024706Phase 2
• Oral Metronomic Capecitabine Combined With Pyrotinib in ADC-treated HER2-positive Metastatic Breast CancerNot yet recruitingNCT07019337Phase 2
• Impact Of Upadacitinib On The Frequency Of Acute Recurrent Anterior Uveitis In Patients With Axial SpondyloarthritisNot yet recruitingNCT07018206Phase 4
• Intermittent Versus Continuous Venetoclax With Acalabrutinib for CLL/SLLRecruitingNCT07014917Phase 2
• Neoadjuvant Therapy of Iparomlimab and Tuvonralimab Combined With Lenvatinib for Hepatocellular CarcinomaRecruitingNCT07014150Phase 2
• The Efficacy and Safety of Deucravacitinib in Takayasu's ArteritisNot yet recruitingNCT07013838Phase 4
• A 16-week Trial to Investigate the Efficacy and Safety of Delgocitinib Cream 20 mg/g in Adult Participants With Mild to Severe Palmoplantar PustulosisRecruitingNCT07013201Phase 2
• Glofitamab, Polatuzumab Vedotin and Zanubrutinib in First-line Elderly DLBCLRecruitingNCT07012980Phase 2
• A Study of Fruquintinib Plus FOLFIRI as Second-Line Treatment for Participants With Metastatic Colorectal Cancer (FRUITFUL)RecruitingNCT07011576Phase 2
• A Prospective Study to Evaluate the Safety and Efficacy of the Combination Therapy of Irpagratinib, Atezolizumab, and Bevacizumab in Patients With Hepatocellular CarcinomaRecruitingNCT07010497Phase 2
• A Study to Assess the Efficacy and Safety of Firmonertinib Versus Placebo for Adjuvant Treatment in Participants With Stage IB - IIIB NSCLC With Uncommon Epidermal Growth Factor Receptor (EGFR) Mutations, Following Complete Surgical Resection With or Without Adjuvant Chemotherapy（FIRMOST）RecruitingNCT07010419Phase 3
• Genotype-Driven Neoadjuvant Therapy for Locally Advanced Thyroid Cancer: A Real-World Cohort StudyNot yet recruitingNCT07010393Phase 4
• Study to Evaluate the Efficacy and Safety of Oral Rilzabrutinib in Adults With Immune Thrombocytopenia (ITP) Who Failed First-line TreatmentRecruitingNCT07007962Phase 3
• JAK Signaling in DepressionRecruitingNCT07003997Phase 2
• Phase II Trial of Zanubrutinib, Obinutuzumab, Bendamustine (ZGB) as First-Line Therapy for Chronic Lymphocytic Leukemia: A Single-Center StudyNot yet recruitingNCT07003464Phase 2
• A Study of Alectinib and Duvelisib in People With Anaplastic Lymphoma Kinase-Positive Anaplastic Large Cell Lymphoma (ALK+ALCL)RecruitingNCT07001384Phase 1
• Methotrexate, Erlotinib, and Celecoxib for the Treatment of Recurrent/Metastatic Head and Neck Cancer in a Rural Midwest United States PopulationRecruitingNCT06997068Phase 2
• Efficacy and Safety of TYRA-300 in Participants With FGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Bladder CancerRecruitingNCT06995677Phase 2
• Immunological Impact of a Post Cell Therapy Treatment With FLT3 InhibitorsNot yet recruitingNCT06992934Not applicable
• Trifluridine/Tipiracil Plus Regorafenib vs Trifluridine/Tipiracil Plus Bevacizumab for Refractory Metastatic Colorectal CancerRecruitingNCT06992648Phase 3
• Ruxolitinib With Radiation and Temozolomide Compared to Radiation and Temozolomide for Newly Diagnosed GlioblastomaRecruitingNCT06991101Phase 2
• DETERMINE Trial Treatment Arm 06: Capmatinib in Adult Patients With Cancers Harbouring MET DysregulationsRecruitingNCT06988475Phase 2/3
• RVU120 Rollover StudyEnrolling by invitationNCT06987058Phase 2
• A Study of BL-B01D1 Monotherapy, BL-B01D1 in Combination With Lenvatinib, BL-B01D1 in Combination With PD-1 Monoclonal Antibody, and BL-B01D1 in Combination With PD-1 Monoclonal Antibody and Bevacizumab in Patients With Advanced Hepatocellular CarcinomaRecruitingNCT06986785Phase 2
• A Phase 2 Study to Evaluate the Safety and Efficacy of Pacritinib in Relapsed or Refractory Waldenström MacroglobulinemiaRecruitingNCT06986174Phase 2
• A Phase II Study of AK104 Combination With Lenvatinib Versus Lenvatinib for Second-line HCCNot yet recruitingNCT06984718Phase 2
• A Study to Investigate the Efficacy and Safety of Rilzabrutinib in Adult Participants With Graves' DiseaseRecruitingNCT06984627Phase 2
• A Clinical Study on the Efficacy and Safety of Fruquintinib in Combination With PD-1 Monoclonal Antibody and Chidamide in Refractory MSS Metastatic Colorectal CancerRecruitingNCT06979908Phase 2
• A Study to Evaluate the Efficacy, Safety, and Drug Levels of Deucravacitinib (BMS-986165) in Adolescent Participants With Moderate to Severe Plaque PsoriasisRecruitingNCT06979453Phase 3
• FGF19 Overexpression Combination Unified Study in HCC-19RecruitingNCT06978933Phase 2
• A Study of Brepocitinib in Adults With Cutaneous SarcoidosisRecruitingNCT06978725Phase 2/3
• LP-168 and Obinutuzumab for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and Variants of ThisRecruitingNCT06978088Phase 2
• The Efficacy and Safety of Rilzabrutinib in Participants Aged 10 to 65 Years With Sickle-cell DiseaseRecruitingNCT06975865Phase 3
• ZR-MTX for PIOL Phase II TrialRecruitingNCT06973811Phase 2
• A Randomized Study to Compare Post-transplant Cyclophosphamide, Sirolimus, Ruxolitinib and Post-transplant Cyclophosphamide, Sirolimus, Mycophenolate Mofetil to Prevent Graft Versus Host DiseaseRecruitingNCT06973668Phase 2
• Phase II Study of Utidelone Plus Fruquintinib Combination Therapy for Platinum-Resistant Recurrent Ovarian CancerNot yet recruitingNCT06973421Phase 2
• Molecular Genetics Guide the Maintenance Therapy After Allogeneic Hematopoietic Stem Cell TransplantationRecruitingNCT06972641Phase 2/3
• Vebreltinib Plus PLB1004 Versus Platinum-based Doublet Chemotherapy in Patients With EGFRm, MET+, Locally Advanced or Metastatic NSCLC Following EGFR-TKI FailureNot yet recruitingNCT06970782Phase 3
• A Study Evaluating Furmonertinib Plus Platinum-based Doublet Chemotherapy Versus Osimertinib in Patients With Epidermal Growth Factor Receptor (EGFR) Sensitizing Mutation-Positive Non-squamous Non-Small Cell Lung Cancer (NSCLC) and Brain MetastasesRecruitingNCT06970639Phase 3
• Safety and Efficacy of Anlotinib in the Treatment of Recurrent CraniopharyngiomaRecruitingNCT06970145Phase 1/2
• Study of SY-5933 Plus CT-707 in Advanced Solid Tumors With KRAS p.G12C MutationNot yet recruitingNCT06970132Phase 1/2
• MWA With or Without Furmonertinib for Early-Stage Non-Small Cell Lung CancerNot yet recruitingNCT06969781Not applicable
• A Study on the Efficacy and Safety of Golidocitinib Combined With Tislelizumab and Chemotherapy as First-line Treatment for Advanced NSCLCRecruitingNCT06969612Phase 1
• Phase II Study of Combined Pirtobrutinib, Venetoclax and Obinutuzumab (PVO) Time-limited Treatment for Patients With Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL).RecruitingNCT06967610Phase 2
• A Phase Ib/II Clinical Study Evaluating the Safety and Efficacy of Tislelizumab in Combination With Golidocitinib and Selinexor for the Treatment of R/R NKTCLRecruitingNCT06966154Phase 1/2
• Pharmacokinetics (PK) and Safety of Zanzalintinib in Participants With Moderate Hepatic Impairment (HI)RecruitingNCT06962332Phase 1
• Imatinib and Trametinib for KRAS-mutated Solid TumorRecruitingNCT06962254Phase 1
• XL092 for the Treatment of Locally Advanced or Metastatic Radioiodine Refractory Differentiated Thyroid CancerRecruitingNCT06959641Phase 2
• Zanzalintinib for the Treatment of Advanced Thyroid Cancer Before SurgeryRecruitingNCT06959511Phase 2
• The Impact of Intelligent Patient Management Model on Medication Adherence of Pyrotinib Compared to Traditional Patient Management Model: a Prospective, Multicenter, Randomized Controlled Clinical StudyRecruitingNCT06958627Phase 2/3
• Zanzalintinib Combined With Eribulin in Advanced Liposarcoma and LeiomyosarcomaRecruitingNCT06957431Phase 1
• Umbrella Trial of Adjuvant Therapy in Completely Resected High-risk Stage IA-IB NSCLC: Focus on Driver MutationsNot yet recruitingNCT06955325Phase 3
• Prospective, Single-arm, Phase II Clinical Study of Irinotecan Hydrochloride Liposome Injection Combined With Platinum and Immune Checkpoint Inhibitors Combined With Anlotinib for the Maintenance of Extensive Small Cell Lung Cancer After First-line InductionNot yet recruitingNCT06951841Phase 4
• A Study of BL-B01D1 and Almonertinib in Patients With Resectable EGFR+ Stage II-IIIB NSCLCRecruitingNCT06951464Phase 2
• Pirtobrutinib and Mosunetuzumab for the Treatment of Relapsed/Refractory Grades 1-3A Follicular Lymphoma, PROMOTE-FL TrialRecruitingNCT06948786Phase 2
• Syk Inhibition in MItigating Lung Allograft Rejection (SIMILAR): A Trial to Evaluate the Safety and Tolerability of Fostamatinib in Lung Transplant Patients With Donor-Specific AntibodiesRecruitingNCT06948097Phase 1
• A Study of Almonertinib Combined With Palbociclib in Patients With Advanced Solid Tumors Harboring KRAS MutationsRecruitingNCT06947811Phase 1/2
• Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine TumorsRecruitingNCT06943755Phase 2/3
• Zanubrutinib Combined With BR in the First-line Treatment of Waldenström's MacroglobulinemiaNot yet recruitingNCT06942507Not applicable
• Tirabrutinib Maintenance Versus Placebo in Patients With Primary CNS Lymphoma in Complete Remission (JCOG2104)RecruitingNCT06940791Phase 2
• Interventional Study to Evaluate the Combination of Palbociclib + Sunitinib as a Treatment for Advanced Solid TumorsRecruitingNCT06940349Phase 1/2
• Dasatinib and Quercetin With CAR-T Therapy for the Treatment of Patients With Relapsed or Refractory Multiple MyelomaRecruitingNCT06940297Phase 2
• Maintenance Zanzalintinib With Etoposide After HDCT in GCTRecruitingNCT06937866Phase 1/2
• MAGIC Ruxolitinib for aGVHDRecruitingNCT06936566Phase 2
• Study of ABBV-637 or ABBV-155 With ERAS-801 for People With GlioblastomaRecruitingNCT06934889Phase 1
• Cabozantinib and Nivolumab Among Older Patients With Renal Cell CarcinomaRecruitingNCT06934057Phase 4
• Benmelstobart, Anlotinib and Chemotherapy as First-line Treatment for Extensive-stage Small-cell Lung CancerNot yet recruitingNCT06931145Phase 4
• Long Covid (LC)-REVITALIZE - A Long Covid Repurposed Drug StudyRecruitingNCT06928272Phase 3
• Zanzalintinib Maintenance in Patients With High Grade Neuroendocrine Neoplasms (HG-NENs)RecruitingNCT06926634Phase 2
• SHR0302 Combined With PD-1/PD-L1 Inhibition for Treatment naïve or Acquired Resistant to Immunology NSCLCNot yet recruitingNCT06925048Phase 2
• Baricitinib in the Treatment of Kohlmeier-Degos Disease in Patients With Neurological InvolvementRecruitingNCT06923072Phase 2
• A Study to Evaluate TAR-210 Versus Intravesical Chemotherapy Treatment in Participants With High Risk Non-Muscle-Invasive Bladder CancerRecruitingNCT06919965Phase 3
• Safety and Preliminary Anti-Tumor Activity of TYRA-430 in Advanced Hepatocellular Carcinoma and Other Solid Tumors With Activating FGF/FGFR Pathway AberrationsRecruitingNCT06915753Phase 1
• Dose Finding Study of Zanzalintinib With Pembrolizumab and Cetuximab in Head and Neck SCCRecruitingNCT06912087Phase 1
• Tepotinib vs Standard Treatment in Patients With Advanced MET Exon 14 Mutated Non-Small Cell Lung Cancer Previously TreatedRecruitingNCT06908993Phase 3
• Glumetinib Combined With Osimertinib Treatment for Non-Small Cell Lung Cancer PatientsNot yet recruitingNCT06908772Phase 2/3
• A Phase II Nationwide, Fully Decentralized, Telemedicine Study of Pemigatinib in Adult Patients With Advanced or Metastatic Pancreatic Cancer With FGFR Genetic AlterationsRecruitingNCT06906562Phase 2
• A Multinational Study Assessing an Oral EGFR Inhibitor, DZD6008 in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN1)RecruitingNCT06905197Phase 1
• Efficacy and Safety of Sintilimab Combined With Lenvatinib and HAIC for Neoadjuvant Therapy of Borderline Resectable HCCRecruitingNCT06904014Phase 2

← Tyrosine Kinase Inhibitors overview